Related Experiment Video
Updated: Mar 15, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14.0K
Targeting intratumoral androgens: statins and beyond
Michael T Schweizer1, Evan Y Yu2
1Division of Oncology, Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Therapeutic Advances in Medical Oncology
|September 2, 2016
Summary
Androgen deprivation therapy (ADT) resistance in prostate cancer is linked to intratumoral androgen production and transport. Targeting these mechanisms, like androgen biosynthesis and transport, offers new therapeutic strategies for castration-resistant prostate cancer (CRPC).
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Androgen deprivation therapy (ADT) is a primary treatment for advanced prostate cancer.
- Resistance to ADT leads to castration-resistant prostate cancer (CRPC), a lethal disease progression.
- Androgen maintenance in the tumor microenvironment is crucial for CRPC development.
Purpose of the Study:
- To explore the mechanisms of androgen maintenance in prostate cancer.
- To identify therapeutic strategies targeting intratumoral androgen biosynthesis and transport.
- To investigate the role of steroidogenic enzymes and androgen transporters in CRPC.
Main Methods:
- Review of preclinical and clinical data.
- Analysis of drugs targeting androgen biosynthesis (e.g., CYP17, AKR1C3 inhibitors like abiraterone).
- Investigation of drugs targeting androgen transporters (e.g., SLCO inhibitors like statins).
Main Results:
- Intratumoral androgen biosynthesis and active transport maintain androgen levels in CRPC.
- Inhibitors of CYP17 and AKR1C3 show potential in targeting androgen biosynthesis.
- Statins are being investigated for their ability to inhibit androgen transport.
Conclusions:
- Targeting intratumoral androgen biosynthesis and transport represents a promising therapeutic avenue for CRPC.
- Developing drugs that inhibit these specific mechanisms could overcome ADT resistance.
- Further research into these pathways may lead to more effective treatments for advanced prostate cancer.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:26Targets for Drug Action: Overview
11.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.0K
01:15Drugs that Stabilize Microtubules
2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
01:29Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73